DailyIQ
Last updated just now

THC·Tenet Healthcare Corporation

$.
-. (-.%)
After Hours
High
$205.94
Open
$204.09
Market Cap
17.38B
52W High
$247.21
Low
$194.08
P. Close
$195.00
P/E
10.21
52W Low
$146.60
Fwd P/E
11.01
DailyIQ Est.
$251.97
Technical Score (1D)
77
BUY
News Sentiment
70
BULLISH
Wells Fargo’s latest research note upgrades Tenet Healthcare to an Overweight rating and lifts its price target from $213 to $231, signaling a stronger conviction in the company’s earnings trajectory. The upgrade stems from the firm’s recent operational improvements and a projected uptick in revenue, which analysts believe will translate into higher profitability over the next few quarters. This rating shift is likely to bolster investor confidence, potentially increasing demand for THC shares as traders adjust their portfolios to reflect the new outlook. The higher price target also suggests a broader upside potential, which may attract short‑term traders looking for a catalyst. In the coming days, the market will be keenly watching Tenet’s next earnings release, as it will confirm whether the projected earnings growth materializes. Additionally, any shifts in healthcare reimbursement policies—particularly changes in Medicare or Medicaid payment structures—could materially affect Tenet’s revenue mix and valuation. Traders should also keep an eye on the company’s cost‑control initiatives, as they are a key driver of the improved earnings outlook. Finally, monitoring the broader healthcare sector’s sentiment will help gauge whether the Overweight upgrade will ripple through peers or remain isolated to Tenet.
Earnings Summary
Tenet Healthcare Corporation operates a diversified network of acute care hospitals and ambulatory surgery centers, delivering a broad spectrum of medical services that places it firmly within the medical care facilities sector. The company’s most recent quarterly results show a robust performance, with Q4 2025 revenue rising to $5.527 billion from $5.072 billion in Q4 2024 and EPS increasing from $3.44 to $4.70, both surpassing analyst expectations of $5.5266 billion and $4.0934 respectively; the Q4 2024 earnings also beat the $2.83235 estimate. Historically, Tenet has consistently outperformed estimates in the two quarters reported, and its revenue growth has been steady, though the company’s cost base is expanding, raising questions about long‑term margin sustainability. Recent analyst commentary highlights a surge in investor attention, with Barclays upgrading Tenet to Overweight and raising its price target to $240, while concerns over less favorable nurse retirement benefits have surfaced, potentially impacting labor costs and recruitment; these developments may influence the company’s operating margins and are likely to be scrutinized in the upcoming July 24 earnings release. Investors should watch for any adjustments to nurse benefit policies, updates on admission growth, and the company’s guidance for Q2 2026, as these factors will be critical in assessing Tenet’s ability to maintain earnings momentum amid rising labor and operational expenses.

EPS

EstBeatMiss
$2.55$3.16$3.77$4.37$4.98Q4'24Q4'25Q2'26
QtrEstActual+/−
Q2'26$4.22 - -
Q4'25$4.09$4.70+14.8%
Q4'24$2.83$3.44+21.5%

Revenue

EstBeatMiss
$5.0B$5.2B$5.3B$5.4B$5.6BQ4'24Q4'25Q2'26
QtrEstActual+/−
Q2'26$5.5B - -
Q4'25$5.5B$5.5B+0.0%
Q4'24 - $5.1B -

Market Data

THC Stock Snapshot

THC is currently trading at $195.00, giving Tenet Healthcare Corporation a market cap of 17.38B and a P/E ratio of 10.2. Today's range spans $194.08–$205.94, with shares opening at $204.09 and moving up $0.00 (0.0%) from the prior close. DailyIQ's technical score sits at 77/100 (BUY) with a news sentiment reading of 70/100.

Over the past year THC has traded between $146.60 and $247.21 - the current price is +33.0% off the 52-week low and -21.1% from the high. 29 analysts cover the stock with a Buy consensus and a mean 12-month target of $244.19 (range $210.00–$288.00), implying upside of +25.2%.

Tenet Healthcare Corporation (THC) is a large-cap in Healthcare with 17.38B in market cap, and the current setup is one of the cleaner bullish reads in the space. Technical score: 77/100 (BUY). Sentiment: bullish at 70/100. Price: $195.00 (in the middle of its 52-week range). The current P/E ratio stands at 10.2. The 52-week range of $146.60–$247.21 provides structural context - and the current technical/sentiment alignment is the type of setup that attracts both momentum and growth-oriented capital.

The combination of a BUY signal (77/100) and bullish news sentiment (70/100) puts THC on the screens of active managers who run quality-momentum overlays — a cohort that can build meaningful positions at 17.38B in Healthcare market cap without immediately moving the stock. At $195.00 (in the middle of its 52-week range in the $146.60–$247.21 range), the entry discipline is clean and the potential re-rating if sentiment continues to improve is meaningful.